INTRODUCTION {#sec1-1}
============

Hepatitis C virus (HCV) infects an estimated 170 million persons worldwide.\[[@ref1]\] HCV infection is a major health problem in most parts of the world, as it can lead to chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma.\[[@ref2]\] If untreated, chronic HCV infection can lead to significant morbidity and mortality.\[[@ref3][@ref4]\] Hepatitis C genotype-4 is the most common type in the Middle East, including Saudi Arabia and Africa.\[[@ref5][@ref6]\] The preliminary treatment reports with conventional interferon monotherapy had yielded disappointing sustained viral response rate of 10%--15%.\[[@ref7]\] Since then, significant advances have been made in the treatment of HCV using pegylated interferon α-2a or α-2b plus ribavirin combination therapy. Sustained virologic response (SVR) rates \> 50% have been reported with the use of combination therapies.\[[@ref8]\] The ability to accurately predict the response of HCV patients to antiviral therapy is of great interest. Host and viral factors, such as HCV genotype, baseline viral load, fibrosis, body weight, and age, influence the response to therapy and can help predict treatment outcomes.\[[@ref9]\] Once treatment is initiated, on-treatment markers of response can further aid in predicting treatment outcomes. These markers include rapid virologic response (RVR, undetectable HCV-RNA at week 4 of therapy), early virologic response (EVR, undetectable HCV-RNA or ≥2 log~10~ decrease in HCV-RNA level from baseline at week 12 of therapy).\[[@ref10]\] They can be assessed before therapy is started (pretreatment predictors) or during therapy (on-treatment predictors). Preferably, the on-treatment predictors should be available early in the treatment course so that patients who are unlikely to respond can have their treatment stopped and those who are likely to respond are encouraged to complete therapy.

The predictors of response to genotype-4 are not well represented in the large registration trials of antiviral therapy because most of the data were on genotype-1.\[[@ref11]\] Currently, this gap in medical knowledge has been largely filled by investigators from Saudi Arabia, Egypt, and Kuwait, where genotype-4 is predominant.\[[@ref12]--[@ref14]\] Data on predictors of response to therapy are limited and there is, therefore, a need for further studies. Thus, the aims of this study were to assess SVR in patients with CHC infection and to assess pre- and on-treatment predictors of response.

MATERIALS AND METHODS {#sec1-2}
=====================

Patient population {#sec2-1}
------------------

Data from 48 patients with chronic hepatitis C treated at King Fahd Hospital of the University, Al-Khobar, between January 2005 and December 2010 were analyzed. The following conditions were excluded: coinfection with hepatitis B or human immunodeficiency viruses, active substance abuse, autoimmune hepatitis, hemochromatosis, α1-antitrypsin deficiency, Wilson\'s disease, and hepatic decompensation. Patients with serum creatinine above 1.5 mg/dL, absolute neutrophil count (ANC) below 750/ μL, platelet count below 50,000/μL, or hemoglobin below 10 g/dL at baseline were excluded from the study. None of our patients consumed alcohol.

Clinical and laboratory assessment {#sec2-2}
----------------------------------

Our study included patients with confirmed diagnosis of CHC by detectable anti-HCV (ELISA III), detectable HCV-RNA in serum within a month before the beginning of the treatment schedule, normal or elevated alanine aminotransferase level (ALT) (\>40 IU/L and \<400 IU/L), and/or liver biopsy indicating chronic hepatitis within 6 months before treatment. Patients' demographic and clinical data were obtained by a careful review of their hospital charts and electronic records. Each patient\'s age, gender, routine laboratory tests (complete blood count, biochemical tests), risk factors for contracting HCV infection, treatment side effects were documented on a data extraction sheet. All patients were clinically, hematologically, and biochemically evaluated at weeks 4, 12, 24, 48, and 72 of treatment follow-up or as needed.

Virologic assessment {#sec2-3}
--------------------

Serum HCV-RNA levels and HCV genotype were measured using an automated extraction system (Cobas Amplicor) Abbott Real Time M2000 (RT-PCR technology) with a HCV-RNA detection rate range of 30--100,000,000 IU/mL. An Internal Control is included in the assays to monitor any possible amplification inhibitors. During the treatment course, serum HCV-RNA level was measured at treatment weeks 4, 12, 24, and 48, and 24 weeks after the end of treatment.

Definitions {#sec2-4}
-----------

The following definitions were used to assess the collected data:

*Rapid viral response* was defined as undetectable serum HCV RNA after 4 weeks of initiation of pegylated interferon and ribavirin combination therapy.

*Early viral response* was defined as ≥2 log decline in serum HCV-RNA level from baseline or undetectable HCV-RNA in serum after 12 weeks of initiation of pegylated interferon and ribavirin combination therapy.

*End of treatment response* was defined as undetectable serum HCV-RNA at the end of treatment.

*Sustained viral response* was defined as undetectable HCV RNA 24 weeks after the end of full course of pegylated interferon and ribavirin combination therapy.

Liver histology {#sec2-5}
---------------

Liver biopsy was performed at baseline, in chronic HCV patients infected with genotypes 1 or 4 only, by an 18-gauge Monopty liver biopsy (Bard Technologies, Covington, GA, USA) needles. Necroinflammation and fibrosis were assessed using the Metavir score.\[[@ref15]\] Steatosis was assessed as the percentage of hepatocytes containing macrovesicular fat droplets. It was graded as 0 \[absent (\<5%)\], 1 \[moderate (5%--30%)\], and 2 \[severe (\>30%)\]. Patients with genotypes 1 or 4 who declined to have a liver biopsy had the option of an alternative noninvasive liver fibrosis test, such as FiboTest-ActiTest^®^ (Biopredictive, France).

Treatment regimen {#sec2-6}
-----------------

The patients were treated either with pegylated interferon-alpha 2a (PEGASYS, 180 μg per week) or with weight-based dosing of pegylated interferon-alpha 2b (PEG-INTRON, 1.5 μg/kg per week) plus ribavirin (1000--1200 mg/day for body weight \<75 or ≥75 kg, respectively). Patients with genotype 2 or 3 were treated for 24 weeks, whereas those with genotypes 1 and 4 were treated for 48 weeks. Treatment was stopped at week 24 if serum HCV-RNA was still detectable. Patients with detectable serum HCV-RNA 6 months after completion of treatment were characterized as nonresponders in the analyses. To maintain the starting dose combination therapy, the patients were given erythropoietin and granulocyte-colony stimulating factor if they developed treatment-induced anemia (\<10 g/ dL) or neutropenia (ANC below 750/μL), respectively.

Statistical analysis {#sec2-7}
--------------------

Descriptive data are provided as percentages, mean ± SD for normally distributed data or median \[interquartile range (IQR)\] for non-normal data. Quantitative data were analyzed by Student\'s *t* test for normally distributed data and by Mann--Whitney *U* test for non-normally distributed data. Variables achieving statistical significance in univariate analysis were included in stepwise binary logistic regression analysis using a backward selection method. The magnitude of these associations is reported as the odds ratio (OR with 95% CI). *P* values \< 0.05 were considered significant. All analyses were conducted with the PASW 18 software (IBM-SPSS Inc).

This study was conducted in accordance with the Helsinki Declaration and was approved by the ethics committee of the University of Dammam.

RESULTS {#sec1-3}
=======

Baseline and clinical characteristics {#sec2-8}
-------------------------------------

Of the 48 patients included in this study, 25 (52%) were women and 23 (48%) were men; their mean age was 43 ± 10 years. Baseline characteristics of these 48 patients are presented in [Table 1](#T1){ref-type="table"}. Twenty-seven percent were chronically infected with HCV genotype-1, 8.3% genotype-2, 14.6% genotype-3, and 50% genotype-4. The median pretreatment quantitative HCV-PCR level was 700,000 IU/L (IQR: 238,000--700,000). Twenty-six (54%) had liver biopsies, which showed grade 0--1 in 9 (34.5%) and grade 2--3 in 17 (65.5%). Seventeen patients (46%) had fibrosis between stage 0--2, whereas 7 (27%) had advanced fibrosis and 2 were cirrhotic (8%). The mean hemoglobin level was 13.8 ± 1.7 g/dL; ALT was elevated (≥40 IU/L) in 42 (88%). Forty-two patients (87.5%) were treatment naïve. Thirty-nine (81%) were treated with Peginterferon α-2a and 9 (19%) with Peginterferon α-2b.

Of the 48 patients, 30% had a history of prior surgery or blood transfusion, 6% a history of dental treatment, 4% had needle stick injury, and the remaining 60% were incidentally detected to be HCV positive.

###### 

Patients\' characteristics at baseline and response to treatment

![](JFCM-20-35-g001)

All patients experienced treatment related side effects of mainly flu-like illness. One patient with genotype-3 developed major side effects (suicide attempt after discontinuing antidepressant therapy) and pegylated interferon was discontinued for 2 weeks, yet the virus was cleared. Eleven (23%) patients developed neutropenia and required hematopoietic support. Other reported side effects were thyroid dysfunction (hypothyroidism or hyperthyroidism), hair loss, anorexia, and itching. The remainder of the patients completed treatment without a reduction of the dose or a discontinuation.

Response to treatment {#sec2-9}
---------------------

The overall SVR rate was 75% (36/48) and among genotype-4 patients was 83.3% (20/24). Of the remaining 12, 5 (10.4%) were primary nonresponders and 7 (14.6%) relapsers. The SVR rates among different genotypes are summarized in Figure [1](#F1){ref-type="fig"}. RVR was achieved in 12 (25%) and EVR in 41 patients (85%). Two cirrhotic patients with genotype-4 had an SVR rate of 50%. Hepatic fibrosis showed no difference in SVR. Similarly, younger age (\<40 years) and baseline serum alanine aminotransferase (ALT) were also not associated with SVR.

![Sustained virologic response rates among different genotypes](JFCM-20-35-g002){#F1}

Factors predictive of SVR {#sec2-10}
-------------------------

On univariate logistic regression analysis, low viral load (\<500,000 IU/L) (*P* = 0.078), genotypes-2 and -3 (*P* = 0.039), genotype-4 (*P* = 0.024), RVR (*P* = 0.086), and EVR (*P* = 0.001) were predictive of SVR. In contrast, age (*P* = 0.372), elevated serum ALT (*P* = 0.148), gender (*P* = 0.407), and lower body mass index (BMI) (≤30 kg/ m^2^) (*P* = 0.657) were not predictive of SVR \[[Table 2](#T2){ref-type="table"}\]. On multivariate logistic regression analysis, including the baseline predictors outlined in the methods section, only genotype-4 (*P* = 0.026) remained in the model predictive of SVR. When on-treatment variables were included, EVR (*P* = 0.048) and baseline viral load (*P* = 0.003) were selected as independent predictors \[[Table 3](#T3){ref-type="table"}\].

###### 

Factors associated with sustained virologic response in 48 patients with hepatitis C virus: univariate logistic regression analysis
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###### 

Factors associated with sustained virologic response in 48 patients with hepatitis C virus: multiple logistic regression analysis
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DISCUSSION {#sec1-4}
----------

The goal of treatment in patients with chronic HCV infection is to eradicate the virus, which is characterized by the attainment of an SVR. Treatment of HCV patients with the combination therapy in our study was associated with a high SVR rate of 75% in all treated patients and 83.3% in genotype-4 patients. This is likely to be due to the inclusion predominantly of patients who were motivated and adhered to treatment with favorable baseline characteristics, that is, treatment naïve patients (87.5%), predominance of ≤ F2 fibrosis (65%) as well as the use of hematopoietic support, which helped to avoid discontinuation of treatment or reduction in therapy doses. The treatment was tailored to initial treatment response and genotype. The SVR observed in the study is higher than that reported in previous studies, particularly for genotype-4.\[[@ref12][@ref16][@ref17]\] In this study, low viral load (\<500,000 IU/L), genotype-4, and EVR were predictive of SVR.

Gad *et al*.\[[@ref14]\] reported that SVR rate was 54.8% in genotype-4. Furthermore, patients with severe fibrosis (F \> 2) were half as likely to achieve SVR compared with those with mild fibrosis. In this study, liver fibrosis was not used as a predictor of response because of the small number of patients with available biopsy data.

It is well known that predictors of response serve as decision tools for treating physicians to help identify patients who are likely or unlikely to achieve SVR and, thus, reduce the risk of side effects and cost, and spare patients the disappointment of treatment failure.\[[@ref1]\] Of the 5 baseline predictors for SVR originally described by Poynard *et al*,\[[@ref18]\] we were only able to confirm low baseline viremia. This study demonstrates for the first time genotype-4 as an independent baseline predictor of SVR, which most likely is due to its predominance (50%) in our cohort. Our results are similar to those of previous studies\[[@ref13][@ref17][@ref19]\] that identified low viral load, and EVR as independent positive predictors of an SVR.

Age, obesity, and gender were not confirmed as independent baseline predictors. Previous data suggested that obesity, defined as BMI \> 30 kg/m^2^, was a risk factor for nonresponse to antiviral therapy.\[[@ref20][@ref21]\] The mechanism whereby obesity may affect the antiviral response to treatment is not completely understood. BMI has been shown to correlate with the degree of steatosis seen in hepatitis C.\[[@ref22]\]

Other studies\[[@ref13][@ref17]\] defined high viral load as HCV-RNA \> 800,000 IU/mL. Backus *et al*. identified 5944 hepatitis C patients who were treated at Veterans Affairs Health Care with PEG-INF/ribavirin and found that patients with low viremia (500,000 IU/mL) were more likely to respond than patients with a high viral load.\[[@ref23]\] Similarly, our study confirmed low viremia (500,000 IU/mL) and non-1 genotype as strong independent predictors of response to therapy.

Genome-wide association studies have recently identified single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19 that strongly predict treatment response in patients infected with HCV.\[[@ref24]\] Patients with the good-response genotype can be expected to have a 70% likelihood of SVR with standard care of therapy. Similar results were seen with genotype-2/3.\[[@ref25]\] Asselah *et al*,\[[@ref26]\] recently studied IL28B polymorphism in 82 out of 164 HCV genotype-4 patients for response to treatment and found rs12979860 CC genotype associated with better response rate of 81.8%. Thus, incorporating IL28B genotyping into clinical practice may assist treating physicians in planning therapy for HCV infection. The approval of two protease inhibitors for genotype-1\[[@ref27][@ref28]\] will further improve SVR rates as well as shorten therapy.

The main limitations of our study are primarily related to its small sample size and retrospective design. However, our study highlighted the importance of non-1 genotype, EVR and low viral load as positive predictive factors to attaining SVR in this population.

In conclusion, in the present study, sustained virologic response rates to pegylated interferon/ribavirin were 75% in the whole series, and 83.3% among genotype-4 patients. HCV genotype-4, EVR and low baseline viral load were independent positive predictors of an SVR in CHC patients.
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